Intra-Cellular Therapies Share Holder Equity 2013-2022 | ITCI

Intra-Cellular Therapies share holder equity from 2013 to 2022. Share holder equity can be defined as the sum of preferred and common equity items
  • Intra-Cellular Therapies share holder equity for the quarter ending March 31, 2022 was $0.793B, a 29.5% increase year-over-year.
  • Intra-Cellular Therapies share holder equity for 2021 was $0.418B, a 36.38% decline from 2020.
  • Intra-Cellular Therapies share holder equity for 2020 was $0.657B, a 236.84% increase from 2019.
  • Intra-Cellular Therapies share holder equity for 2019 was $0.195B, a 38.62% decline from 2018.
Intra-Cellular Therapies Annual Share Holder Equity
(Millions of US $)
2021 $418
2020 $657
2019 $195
2018 $318
2017 $454
2016 $376
2015 $476
2014 $121
2013 $32
2012 $17
Intra-Cellular Therapies Quarterly Share Holder Equity
(Millions of US $)
2022-03-31 $793
2021-12-31 $418
2021-09-30 $487
2021-06-30 $554
2021-03-31 $612
2020-12-31 $657
2020-09-30 $709
2020-06-30 $380
2020-03-31 $430
2019-12-31 $195
2019-09-30 $227
2019-06-30 $257
2019-03-31 $289
2018-12-31 $318
2018-09-30 $354
2018-06-30 $390
2018-03-31 $423
2017-12-31 $454
2017-09-30 $319
2017-06-30 $340
2017-03-31 $353
2016-12-31 $376
2016-09-30 $399
2016-06-30 $426
2016-03-31 $453
2015-12-31 $476
2015-09-30 $502
2015-06-30 $204
2015-03-31 $222
2014-12-31 $121
2014-09-30 $134
2014-06-30 $139
2014-03-31 $143
2013-12-31 $32
2013-09-30 $40
2013-06-30 $-0
2013-03-31 $-0
2012-12-31
2012-09-30 $0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $5.204B $0.084B
Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00